CoChat

Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases

Open access
Liu, Chunjian, Lin, James, Wrobleski, Stephen T., Lin, Shuqun, Hynes, John, Wu, Hong, Dyckman, Alaric J., Li, Tianle, Wityak, John, Gillooly, Kathleen M., Pitt, Sidney, Shen, Ding Ren, Zhang, Rosemary F., McIntyre, Kim W., Salter-Cid, Luisa, Shuster, David J., Zhang, Hongjian, Marathe, Punit H., Doweyko, Arthur M., Sack, John S., Kiefer, Susan E., Kish, Kevin F., Newitt, John A., McKinnon, Murray, Dodd, John H., Barrish, Joel C., Schieven, Gary L., Leftheris, Katerina · 2010 · Journal of Medicinal Chemistry
Cited by 56

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The discovery and characterization of 7k (BMS-582949), a highly selective p38α MAP kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid arthritis, is described. A key to the discovery was the rational substitution of N-cyclopropyl for N-methoxy in 1a, a previously reported clinical candidate p38α inhibitor. Unlike alkyl and other cycloalkyls, the sp(2) character of the cyclopropyl group can confer improved H-bonding characteristics to the directly substituted amide NH. Inhibitor 7k is slightly less active than 1a in the p38α enzymatic assay but displays a superior pharmacokinetic profile and, as such, was more effective in both the acute murine model of inflammation and pseudoestablished rat AA model. The binding mode of 7k with p38α was confirmed by X-ray crystallographic analysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm100540x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 56

Metadata

Authors
Liu, C., Lin, J., Wrobleski, S. T., Lin, S., Hynes, J., Wu, H., Dyckman, A. J., Li, T., Wityak, J., Gillooly, K. M., Pitt, S., Shen, D. R., Zhang, R. F., McIntyre, K. W., Salter-Cid, L., Shuster, D. J., Zhang, H., Marathe, P. H., Doweyko, A. M., Sack, J. S., Kiefer, S. E., Kish, K. F., Newitt, J. A., McKinnon, M., Dodd, J. H., Barrish, J. C., Schieven, G. L., & Leftheris, K.
Venue
Journal of Medicinal Chemistry
Published
2010-08-30
Volume
53
Issue
18
Pages
6629-6639
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2090277801
Cited by
56
References
1
FWCI
2.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases. https://app.cochat.ai/papers/10.1021/jm100540x
The paper
Liu, C., Lin, J., Wrobleski, S. T., Lin, S., Hynes, J., Wu, H., Dyckman, A. J., Li, T., Wityak, J., Gillooly, K. M., Pitt, S., Shen, D. R., Zhang, R. F., McIntyre, K. W., Salter-Cid, L., Shuster, D. J., Zhang, H., Marathe, P. H., Doweyko, A. M., . . . Leftheris, K. (2010). Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm100540x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.